Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 3, 2012, Pages 313-317

  Van Herck, Koen ^a,b   Crasta, Priya Diana ^c   Messier, Marc ^c   Hardt, Karin ^c   Van Damme, Pierre ^a  

^a Vaccine and Infectious Disease Institute (WHO Collaborating Centre)   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

HAV; Hepatitis; Immune memory; Monovalent; Persistence; Vaccine

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PROVOCATION TEST; SERODIAGNOSIS; TREATMENT DURATION; VACCINATION;

EID: 84860384577     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.3.18617     Document Type: Article

References (15)

1. World Health Organization (WHO). 2000. Hepatitis A position paper. Wkly Epidemiol Rec 75:38-42. World Health Organisation, Dept. of Communicable diseases surveillance and Response. WHO/CDC/CSR/LYO/ 2002.2: Hepatitis B. Available: http://www.who.int/csr/disease/hepatitis/ HepatitisB_whocdscsrlyo2002_2.pdf. [Accessed on August 05, 2011].
2. Andersson KL, Friedman LS, Hepatitis A. A travelling target. Arch Intern Med 2010; 20:1818-9; http://dx.doi.org/10.1001/archinternmed.2010.412
3. Askling HH, Rombo L, Andersson Y, Martin S, Ekdahl K. Hepatitis A risk in travelers. J Travel Med 2009; 16:233-8; PMID:2012 19674261; http://dx.doi.org/10.1111/j.1708-8305.2009.00307.x
4. André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 2002; 1:9-23; PMID:12908508; http://dx.doi.org/10.1586/14760584.1.1.9
5. Nothdurft HD. Hepatitis A vaccines. Expert Rev Vaccines 2008; 7:535-45; PMID:18564009; http://dx.doi.org/10.1586/14760584.7.5.535
6. Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005; 4:459-71; PMID:16117704; http://dx.doi.org/10.1586/ 14760584.4.4.459
7. Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008; 198:1776-82; PMID:18976095; http://dx.doi.org/10.1086/593335
8. López EL, Contrini MM, Mistchenko A, Debbag R. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J 2010; 29:568-70; PMID:20195189
9. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004; 72:194-6; PMID:14695659; http://dx.doi.org/10.1002/jmv.10574
10. Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011; 83:1885-91; PMID:21915861; http://dx.doi.org/10.1002/jmv.22200
11. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1-7; PMID:11130881; http://dx.doi.org/10.1002/1096-9071(200101)63:1〈1:: AID-JMV1000〉3.0.CO;2-U
12. Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H,Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007; 25:927-31; PMID:17005304; http://dx.doi.org/10.1016/j.vaccine.2006.08.044
13. Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60:1-7; PMID:10568755; http://dx.doi.org/10.1002/(SICI)1096- 9071(200001)60:1〈1::AID-JMV1〉3.0.CO;2-H
14. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1-7; PMID:11130881; http://dx.doi.org/10.1002/1096- 9071(200101)63:1〈1:: AID-JMV1000〉3.0.CO;2-U
15. Van Damme P, Matheï C, Thoelen S, Meheus A, Safary A, André FE. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994; 44:435-41; PMID:7897376; http://dx.doi.org/10.1002/jmv.1890440422